Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) announced preliminary unaudited third-quarter 2026 revenue expected to range between $9.8 million and $10.0 million, representing what the company describes as a record-breaking quarterly result. The figures would surpass the Bloomberg mean analyst consensus of $6.78 million by approximately 45% to 47%, a significant beat that may draw investor attention. Gross margin is also expected to exceed 70% for the quarter ended September 30, 2026.

Key Points

  • Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) is a Toronto-based commercial-stage medical device company focused on interventional MRI procedures.
  • Preliminary Q3 2026 revenue is expected in the range of $9.8 million to $10.0 million, described by the company as a record quarterly result.
  • Year-over-year revenue growth is expected at approximately 85% to 89% versus $5.3 million in Q3 2025; sequential quarter-over-quarter growth is expected at approximately 292% to 300% versus $2.5 million in Q2 2026.
  • Investors may be watching the full Q3 2026 results call scheduled for November 5, 2026, after market close.

Preliminary Revenue Figures Far Exceed Wall Street Expectations

Profound Medical's preliminary results indicate Q3 2026 revenue approximately 45% to 47% above the Bloomberg mean analyst consensus of $6.78 million, compiled as of October 7, 2026. The company attributes the strong performance to increased commercial activity across its installed base and new customer accounts. CEO and Chairman Arun Menawat described the expected results as "a historic milestone," citing commercial momentum building behind the company's technology. These figures remain preliminary and unaudited, and the company cautions that actual revenues may differ from the estimates disclosed.

Year-Over-Year and Sequential Growth Reflect Accelerating Commercial Activity

Compared with $5.3 million reported in Q3 2025, the anticipated Q3 2026 revenue would represent year-over-year growth of approximately 85% to 89%. On a sequential basis, the expected result would mark growth of approximately 292% to 300% relative to $2.5 million in Q2 2026. The release suggests the acceleration reflects both utilisation of the existing installed base and expansion into new customer accounts. Gross margin is again expected to exceed 70%, which the company states reflects continued progress in its commercial operations and scale.

TULSA-PRO and Sonalleve Drive Profound's Commercial Platform

Profound Medical's commercial portfolio centres on two MRI-guided platforms. TULSA-PRO® enables incision-free prostate tissue ablation under real-time MRI guidance, with clearances across the United States, Europe, Canada, and several other markets. The company also commercialises Sonalleve®, which provides non-surgical treatment options for conditions including bone metastases pain palliation, uterine fibroids, and adenomyosis. The release states the company remains focused on supporting customer adoption, increasing utilisation of its installed base, and building a profitable growth company over the long term.

Full Q3 2026 Results Scheduled for November 5, 2026

Profound Medical intends to report complete third-quarter 2026 financial results after market close on Thursday, November 5, 2026, followed by a conference call at 4:30 p.m. ET. The call is expected to cover financial results and business developments for the period. Investors may be watching that disclosure for audited figures, updated guidance, and management commentary on the commercial trajectory of both TULSA-PRO® and Sonalleve®. The immediate share price impact of the preliminary revenue announcement was not clear from available public information.